GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline (GSK) has reached a confidential settlement in the prostate cancer lawsuit filed by Isaac Dixon, without admitting any liability, and the case will be dismissed. GSK continues to stand by the scientific consensus from 16 epidemiological studies since 2019, which suggests no link between ranitidine and cancer. The company reaffirms its commitment to defend its interests and manage litigation in alignment with shareholder values.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
